Can a single tracer light up cancer's first stop? a trial puts a hybrid dye-and-radioactive marker to the test.
NCT ID NCT06666634
First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time
Summary
This trial tests whether a new hybrid tracer, ICG-99mTc-nanoscan, can replace the standard tracer for sentinel node biopsy in people with penile cancer, melanoma, or oral cancer. The hybrid tracer combines a fluorescent dye with a radioactive marker, potentially allowing surgeons to see lymph nodes both before and during surgery with one injection. Researchers will compare how well the new tracer matches the standard one in identifying sentinel nodes on imaging. The study enrolls 29 adults scheduled for a sentinel node procedure as part of their routine care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a hybrid tracer called ICG-99mTc-nanoscan, combining a fluorescent dye and a radioactive marker to help surgeons locate sentinel lymph nodes
- What this could lead to
- If the new tracer proves as effective as the standard one, it could simplify sentinel node procedures by allowing both preoperative imaging and real-time surgical guidance with a single injection.
- What could go wrong
- This is a small validation study with only 29 participants, so results may not apply broadly. The new tracer might not match the standard's accuracy, and there is a risk of allergic reaction or false negatives.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NKI-AVL
Amsterdam, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer reveal whether immunotherapy is working?
- Can a new nucleotide analogue boost cancer treatment?
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- Botox before the knife: could a Pre-Surgery injection lead to Better-Looking scars?
- Could a Two-Drug combo reawaken the immune system against resistant cancers?
- Could a lighter immunotherapy schedule keep advanced cancers in check?